Loan & DebtAug 3, 2026, 07:06 AM
BioXcel Therapeutics Defers $9M Debt Payment to Aug 31
AI Summary
BioXcel Therapeutics, Inc. entered into the Eleventh Amendment to its Credit Agreement, deferring a principal and interest payment of $9,016,914.47 from July 31, 2026, to August 31, 2026. The amendment also reduced the minimum liquidity covenant from $7.5 million to $6.25 million. The company is now required to secure definitive agreements for full debt repayment or an alternative capital solution by August 10, 2026, and faces restrictions on modifying compensation arrangements until August 31, 2026.
Key Highlights
- Deferred $9,016,914.47 principal and interest payment from July 31, 2026, to August 31, 2026.
- Reduced minimum liquidity covenant from $7.5 million to $6.25 million.
- Required to enter definitive agreements for debt repayment or alternative capital solution by August 10, 2026.
- Prohibited from modifying compensation arrangements for directors, officers, or employees through August 31, 2026.
Price Impact
More from BTAI